Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

dentalcorp Holdings Ltd T.DNTL

Alternate Symbol(s):  DNTCF

dentalcorp Holdings Ltd. is a Canada-based consumer healthcare services company, which is a provider of dental services in Canada. The principal activity of the Company, through its subsidiaries, is to acquire dental practices and provide health care services in Canada. The Company owns and operates a network of 535 dental practices. Its nationwide network is comprised of 1,850 dentists, over 2,400 hygienists, and over 5,400 auxiliary dental health professionals. The Company’s subsidiaries include Dentalcorp Health Services Ltd., DCC Health Services (Quebec) Inc., 1348856 B.C. Ltd. and Dentalcorp Holdings (US) Ltd.


TSX:DNTL - Post by User

Post by retiredcfon Nov 10, 2022 9:34am
206 Views
Post# 35087973

RBC Report

RBC ReportTheir upside scenario target is $19.00. GLTA

November 9, 2022
dentalcorp Holdings Ltd.

Q3/22: Results ahead of estimates; Attractive at an ~8.7x multiple, in our view

Our view: Q3/22 revenues and adj. EBITDA were stronger than RBCe and consensus estimates. Same practice sales growth was +2.4% y/y in Q3, impacted by Hurricane Fiona (vs. +3.1% y/y in Q2). dentalcorp acquired 14 practices with adj. EBITDA (IFRS) of $12.9MM in Q3 at an ~8.1x IFRS EBITDA multiple (8.9x in Q2). Management expects the EBITDA acquisition pace to moderate in Q4 and 2023 to a level of $5-7MM/Q, which should contribute to lower leverage ratios. At ~8.7x EV/EBITDA, we reiterate our Outperform rating with a revised $15 PT (from $18), reflecting the rising rate environments and lower comps.

Key points:
Revenues above RBCe and consensus expectations. GMs increased q/q. dentalcorp reported Q3/22 revenues of $312.1MM (-4.6% q/q; +28.7% y/ y), ahead of RBCe ($310.2MM) and consensus ($310.5MM). Gross margins of 49.5% in the quarter improved q/q (48.6% in Q2) and were above RBCe (48.5%) and consensus (49.0%).

Ahead of expectations on adj. EBITDA. dentalcorp reported Q3/22 adj. EBITDA of $59.3MM on an IFRS basis (including $2.1MM realized FX gain on company's USD cash holdings), ahead of RBCe ($55.9MM) and consensus ($56.6MM). The adj. EBITDA margin of 19.0% was up q/q (18.3%) and above consensus (18.2%) and RBCe (18.0%). Adj. FCF for Q3/22 was $28.8MM, down q/q ($41.7MM in Q2).

Acquired 14 practices ($12.9MM adj. EBITDA) in Q3 at implied ~8.1x IFRS EBITDA multiple. dentalcorp acquired 14 dental practices in Q3/22 for total consideration of $104.1MM (mgmt expects acquired practices to generate ~$12.9MM in annualized adj. EBITDA implying an acquisition multiple of ~8.1x). The company plans to acquire $5-7MM in acquired adj. EBITDA in Q4/22 and a similar modest acquisition pace in 2023 vs. 2022E. dentalcorp will reduce near-term pacing of acquisitions to accelerate de-levering.

Sufficient liquidity for future acquisitions. dentalcorp ended the Sep-22 quarter with ~$133.0MM in cash and ~$700.4MM in debt capacity under its $1.75B senior debt facility (of which ~$1.05B was drawn at quarter-end). Post the quarter close, DNTL effected an interest rate swap agreement providing for a fixed rate of ~6.6% on $500MM of the $1.0B drawn under its $1.75B senior debt facilities resulting its total borrowing costs to ~6.5% based on interest rates and leverage as of the end of Q3/22.

Estimate and PT revisions. We revise our forecasts (see RHS) to incorporate today's guidance of slower pace of acquisitions. We also revise our target multiple lower from 17.0x to 15.0x on 2023E IFRS EBITDA given the de- rating of the comps and incorporating the higher interest rate environment. We believe our multiple is supported by the predictable, non-discretionary nature of dentalcorp's revenues even in an economic downturn.
<< Previous
Bullboard Posts
Next >>